FH:CC News and Press, FILAMENT HEALTH CORP. From 05/12/23

FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , May 12, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage n...

FILAMENT HEALTH ANNOUNCES SPRING 2023 EVENT AND MEDIA APPEARANCES Canada NewsWire VANCOUVER, BC , April 25, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug dev...

FILAMENT HEALTH AND PHARMALA BIOTECH ANNOUNCE RELEASE OF GMP MDMA CAPSULES Canada NewsWire Filament subsidiary Psilo Scientific manufactured the drug product on behalf of PharmAla for distribution to clinical trial customers and authorized patients. VANCOUVER, BC ...

VANCOUVER, British Columbia, April 11, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE:MDMA), a Canadian biotechnology company dedicated to the research and development of clinical-grade LaNeo™ MDMA and novel MDXX compounds, and Filament Health Corp....

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2022 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS Canada NewsWire VANCOUVER, BC , March 31, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage ...

FILAMENT HEALTH ANNOUNCES FDA APPROVAL OF PHASE II CLINICAL TRIAL STUDYING PSILOCYBIN FOR METHAMPHETAMINE USE DISORDER Canada NewsWire The clinical trial will study PEX010, Filament's botanical psilocybin drug candidate VANCOUVER, BC , March 15, 2023 /CNW...

FILAMENT HEALTH ANNOUNCES SECOND PSILOCYBIN SUPPLY AGREEMENT WITH THE CENTRE FOR ADDICTION AND MENTAL HEALTH Canada NewsWire CAMH will study PEX010, Filament's botanical psilocybin drug candidate, in a Health Canada-approved clinical trial for mild cognitive impairment ...

Magdalena Biosciences is focused on developing novel, natural prescription medicines derived from plants for mental health indications including attention-deficit/hyperactivity disorder (ADHD) in adults SAN FRANCISCO, CA / ACCESSWIRE / January 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) t...

FILAMENT HEALTH ANNOUNCES CLINICAL TRIAL APPROVAL IN PARTNERSHIP WITH PSYCHIATRIC CENTRE COPENHAGEN Canada NewsWire Danish psychiatric research hospital will study the effects of Filament's natural psilocybin drug candidate for treating alcohol use disorder VANCOUVER...

Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses Canada NewsWire New venture aligns with Jaguar's mental health Entheogen Therapeuti...